CClinicalTrials.gg
CompletedNCT06723340Updated Mar 14, 2025

Dermatological Assessment of Primary Dermal Irritability Accumulated, Sensitization, Photoallergy and Photosensitization of a Scar Gel

An interventional study of Scar gel in Sensitivity, Contact, Photosensitivity and Phototoxicity, sponsored by Herbarium Laboratorio Botanico Ltda. Completed at 1 site in Brazil. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-14.

Sponsored by Herbarium Laboratorio Botanico Ltda · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Evaluate the potential of Primary Dermal Irritability, Accumulated Dermal Irritability, Dermal Sensitization, Photoallergy and Photosensitization, of health products through the application of Patch Test, proving the safety of the product for topical use. The study will be conducted with a Brazilian sample in which 55 research participants will be included. Depending on the results, the present study may support the claim: dermatologically tested, non-irritating, non-sensitizing, non-photoirritating and non-photosensitizing.

02

Conditions studied

  • Sensitivity, Contact
  • Photosensitivity
  • Phototoxicity
03

In context

Dermatitis, Phototoxic

22 studies on the registry are indexed under Dermatitis, Phototoxic; 1 is open to participants now.

This study's enrollment of 55 is above the median of 35 across 19 interventional studies indexed under Dermatitis, Phototoxic.

Browse Dermatitis, Phototoxic studies →

Lead sponsor

Herbarium Laboratorio Botanico Ltda is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Participants of both sexes aged 18 to 70 years;
  • Phototypes: I, II, III, and IV (For the phototest trial, only phototypes II and III will be considered);
  • Intact skin in the application area;
  • Willingness to follow the trial procedures and attend the center on the specified dates and times for medical evaluations and for application and reading of dressings;
  • Understanding, consent, and signing of the Informed Consent Form (ICF).

Exclusion Criteria:

  • Pregnancy or risk of pregnancy/lactation;
  • Use of anti-inflammatory drugs within 30 days and/or immunosuppressive drugs up to three months before selection;
  • Immunosuppression due to drugs or active diseases;
  • Uncompensated endocrinopathies;
  • Personal history of atopy;
  • Intense sun exposure or tanning sessions up to 15 days before the evaluation or during the study period;
  • Plans to bathe in the sea, pool, or sauna during the study;
  • Practice of water sports during the study;
  • Dermographism;
  • Use of oral or topical treatments with vitamin A acid and/or its derivatives up to one month before the start of the study;
  • Aesthetic and/or dermatological treatments on the body within three weeks prior to selection;
  • Scheduled vaccination during the study period or within three weeks prior to selection;
  • History of sensitization, irritation, or photosensitization to topical products;
  • Active skin conditions (local and/or widespread) that could interfere with study results;
  • Skin reactivity;
  • Use of new medications during the study;
  • Previous participation in studies with the same product;
  • Congenital or acquired immunodeficiency;
  • Clinically significant or current evidence of alcohol or drug abuse;
  • Known or suspected history of intolerance to any ingredient in the study product;
  • History of non-adherence or unwillingness to adhere to the study protocol;
  • Employees of Medcin or the sponsoring company involved in the study, or close family members of an employee involved in the study;
  • Other conditions deemed reasonable by the researcher for disqualification from study participation. If applicable, this must be noted in the clinical record.

Exclusion Criteria for the Phototest:

  • Previous history of conditions exacerbated or triggered by ultraviolet radiation;
  • Use of photosensitizing drugs;
  • History or presence of photodermatoses;
  • Personal or family history of skin cancer.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Experimental

    Scar gel

    Device: Scar gel

Interventions

  • DeviceScar gel

    Scar gel (medical device - topical application)

06

What researchers measure

Primary outcomes

  1. Absence

    Absence of Primary Dermal Irritability Accumulated, Sensitization, Photoallergy and Photosensitization under normal conditions and when exposed to sunlight.

    Time frame: 9 weeks

07

Study locations

1 site
  • Medcin Instituto da Pele Ltda
    Osasco, São Paulo, Brazil
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06723340
Lead sponsor
Herbarium Laboratorio Botanico Ltda
Responsible party
Sponsor
First posted
Dec 9, 2024
Start date
Jan 13, 2025
Primary completion
Feb 20, 2025
Completion
Feb 20, 2025
Last update
Mar 14, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion